iNtRON Biotechnology, Inc.: debt-to-equity, ROE and more
KOSDAQ, Legal name iNtRON Biotechnology, Inc.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 6.4%
- Equity ratio
- 94.0%
- ROE
- -12.8%
- Op. margin
- -137.7%
- Rev. growth
- -10.6%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 4 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | n/a | n/a |
| 2024 | ₩100 | n/a |
| 2023 | ₩100 | n/a |
No cash dividend in the latest fiscal year, or no value reported.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 51.3% | 66.1% | 9.6% | 34.4% | n/a |
| FY2022 consolidated | 32.8% | 75.3% | 5.4% | -10.6% | -52.2% |
| FY2023 consolidated | 1.9% | 98.1% | -10.0% | -34.3% | -31.6% |
| FY2024 consolidated | 3.1% | 97.0% | -3.1% | -81.6% | -33.0% |
| FY2025 consolidated | 6.4% | 94.0% | -12.8% | -137.7% | -10.6% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩29.3B | ₩14.0B | ₩9.6B | ₩6.4B | ₩5.7B |
| Operating profit | ₩10.1B | -₩1.5B | -₩3.3B | -₩5.2B | -₩7.9B |
| Pre-tax income | ₩10.6B | ₩8.3B | -₩10.8B | -₩3.0B | -₩9.0B |
| Net income | ₩9.7B | ₩5.7B | -₩9.7B | -₩2.6B | -₩9.0B |
| Total assets | ₩153.4B | ₩141.0B | ₩98.6B | ₩86.4B | ₩74.3B |
| Total liabilities | ₩52.0B | ₩34.8B | ₩1.9B | ₩2.6B | ₩4.4B |
| Total equity | ₩101.3B | ₩106.2B | ₩96.7B | ₩83.8B | ₩69.9B |
| Paid-in capital | ₩16.9B | ₩17.1B | ₩17.1B | ₩17.1B | ₩17.1B |
| Debt/equity (source value) | 51.3% | 32.8% | 1.9% | 3.1% | 6.4% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1999-01-18
- Listed
- 11/01/26
- Employees
- 77
- Auditor
- 신한회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101111636004
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 인트론바이오Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.